FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Moderate exercise delays time to breast cancer recurrence
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People with breast cancer who are interested in using exercise to reduce risk of recurrence
For premenopausal women with early-stage breast cancer, physical activity may increase the time before cancer returns and spreads. In this study, people with hormone receptor-negative (HR-negative) breast cancer benefited from moderate exercise—more than those with hormone receptor-positive (HR-positive) breast cancer. This study found that outcomes improved when weekly exercise time was between 90 minutes and 5 hours. (Posted 11/14/24)
Read More
Relevance: Medium-High
Research Timeline: Post Approval
Update : News from the FDA: New endometrial cancer approvals
Relevance: Medium-High
Research Timeline: Post Approval
Most relevant for: People with endometrial cancer
The FDA recently approved three new immunotherapy treatments (Jemperli, Imfinzi and Keytruda) for advanced endometrial cancer. (Posted 11/7/24)
Read More
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
Study : Impact of breast cancer and BRCA mutations on fertility preservation
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People considering fertility preservation.
Timely family planning discussions are important for people diagnosed with breast cancer as well as those who have an inherited a BRCA1 or BRCA2 mutation. This study looked at the number of mature eggs recovered when ovaries were stimulated for fertility preservation or preimplantation genetic testing among three groups and found that the number of eggs collected was similar. (Posted 10/31/24)
Read More
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : More research points to the benefits of pancreatic cancer screening
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People undergoing pancreatic cancer screening
People with a family history of pancreatic cancer or those who have an inherited mutation that increases risk may benefit from yearly pancreatic cancer screening. Yearly screening may lead to early diagnosis and longer survival. (Posted 10/8/24)
Este artículo está disponible en español.
Read More
Study : Use of cannabis for cancer symptom management
Most relevant for: People with cancer interested in using cannabis to help manage symptoms.
Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Managing the side effects of advanced endometrial cancer treatment
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People with advanced endometrial cancer
Immunotherapy plus targeted therapy is a treatment option for advanced endometrial cancer that has progressed after prior treatment. People who start the two-drug combination are more likely to have a positive experience if they learn about the possible side effects and when they might occur. The most common side effects and how to manage them are discussed in this review. (Posted 9/25/24)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Combining two anti-HER2 drugs improves outcomes more effectively than one
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with Her2-positive metastatic breast cancer
Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)
Este artículo está disponible en español.
Read More
Relevance: Medium
Research Timeline: Post Approval
Update : News from the FDA: First-line treatment and biosimilars for prostate cancer
Relevance: Medium
Research Timeline: Post Approval
Most relevant for: People with prostate cancer
The FDA recently approved a first-line treatment for non-metastatic, castration-sensitive prostate cancer. Approval was also given to two new drugs known as biosimilars that can be used in place of two already approved biologics to prevent bone weakening, pain or fractures that may occur from certain hormone therapies or from cancer that has spread to the bone. (Posted 9/10/24)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Study : Colorectal cancer in people with Lynch syndrome can include types of cancer found more typically in people without Lynch syndrome
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: People with Lynch syndrome and people with colorectal cancer who may have Lynch syndrome
When people with Lynch syndrome (LS) develop cancer, their tumors typically have a related set of features or biomarkers known as deficient mismatch repair (dMMR) and high microsatellite instability (MSI-High). However, occasionally people with Lynch syndrome have cancers that are proficient in mismatch repair (pMMR or MMR-P) and have microsatellite stability (MSS or MSI-Low) –more like the colorectal cancers found in people without Lynch syndrome. This study shows that 10 percent of people with Lynch syndrome may have these types of cancers. This can change treatment recommendations. (Posted 9/5/24)
Este artículo está disponible en español.
Read More
Relevance: Medium
Research Timeline: Post Approval
Update : News from the FDA: Updates on breast cancer treatment
Relevance: Medium
Research Timeline: Post Approval
Most relevant for: People with BioZorb markers in breast tissue. People who will have a lumpectomy. People interested in cancer-related podcasts.
The FDA updates the risks of using BioZorb Markers, approves a new imaging drug and shares the Oncology Podcast Series. (Posted 8/16/24)
Este artículo está disponible en español.
Read More